
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3581261/publications.pdf Version: 2024-02-01



DETED ROLL

#	Article	IF	CITATIONS
1	Atrial Natriuretic Peptide and Atrial Pressure in Patients with Congestive Heart Failure. New England Journal of Medicine, 1986, 315, 533-537.	27.0	622
2	Correlation of Platelet Calcium with Blood Pressure. New England Journal of Medicine, 1984, 310, 1084-1088.	27.0	556
3	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	1.7	474
4	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	1.7	431
5	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	1.7	400
6	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	1.7	324
7	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	1.7	269
8	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	1.7	221
9	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	1.7	173
10	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	1.7	170
11	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	1.7	163
12	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	1.7	127
13	Renin Profiling to Select Anti hypertensive Baseline Drugs. American Journal of Medicine, 1984, 77, 36-42.	1.5	98
14	Age, race, blood pressure and renin: Predictors for antihypertensive treatment with calcium antagonists. American Journal of Cardiology, 1985, 56, H81-H85.	1.6	95
15	A New Algorithm for the Diagnosis of Hypertension inÂCanada. Canadian Journal of Cardiology, 2015, 31, 620-630.	1.7	88
16	Greater Antihypertensive Efficacy of the Calcium Channel Inhibitor Verapamil in Older and Low Renin Patients. Clinical Science, 1982, 63, 439s-442s.	0.0	84
17	The Role of Adiponectin in Endothelial Dysfunction and Hypertension. Current Hypertension Reports, 2014, 16, 463.	3.5	77
18	Antihypertensive Treatment Using Calcium Antagonists in Combination with Captopril Rather than Diuretics. Journal of Cardiovascular Pharmacology, 1985, 7, S88-S91.	1.9	72

#	Article	IF	CITATIONS
19	Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. Journal of the American College of Cardiology, 1986, 7, 344-348.	2.8	64
20	Plasma Catecholamines and Cardiac, Renal and Peripheral Vascular Adrenoceptor-Mediated Responses in Different Age Groups of Normal and Hypertensive Subjects. Clinical and Experimental Hypertension, 1980, 2, 409-426.	1.3	62
21	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2005, 21, 645-56.	1.7	61
22	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.	1.7	60
23	New Algorithm for the Diagnosis of HypertensionCanadian Hypertension Education Program Recommendations (2005). American Journal of Hypertension, 2005, 18, 1369-1374.	2.0	57
24	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2006, 22, 573-581.	1.7	56
25	Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. American Heart Journal, 1988, 115, 282-288.	2.7	52
26	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2007, 23, 529-538.	1.7	49
27	Calcium antagonists and the second drug for hypertensive therapy. American Journal of Medicine, 1986, 81, 25-29.	1.5	47
28	Parallel Reduction of Calcium-Influx-Dependent Vasoconstriction and Platelet-Free Calcium Concentration with Calcium Entry and ??-Adrenoceptor Blockade. Journal of Cardiovascular Pharmacology, 1984, 6, S1002.	1.9	43
29	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2008, 24, 455-463.	1.7	38
30	The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part IBlood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2004, 20, 31-40.	1.7	38
31	Concomitant Digoxin Toxicity and Warfarin Interaction in a Patient Receiving Clarithromycin. Annals of Pharmacotherapy, 1999, 33, 796-799.	1.9	37
32	Elevated Adrenaline and Increased α-Adrenoceptor-Mediated Vasoconstriction in Essential Hypertension. Journal of Cardiovascular Pharmacology, 1982, 4, S134-S138.	1.9	34
33	Use of Calcium Antagonists as Monotherapy in the Management of Hypertension. American Journal of Medicine, 1984, 77, 11-15.	1.5	34
34	Effects of prazosin in patients with hypertension. Clinical Pharmacology and Therapeutics, 1976, 20, 138-141.	4.7	33
35	Fura-2 used as a probe to show elevated intracellular free calcium in platelets of Dahl-sensitive rats fed a high salt diet. Biochemical and Biophysical Research Communications, 1988, 154, 380-386.	2.1	33
36	Position of Calcium Antagonists in Antihypertensive Therapy. Journal of Cardiovascular Pharmacology, 1985, 7, S21-S27.	1.9	32

#	Article	IF	CITATIONS
37	The Effects of Posture Change and Continuous Positive Airway Pressure on Cardiac Natriuretic Peptides in Congestive Heart Failure. Chest, 1995, 107, 909-915.	0.8	27
38	The 2001 Canadian recommendations for the management of hypertension: Part one-Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Canadian Journal of Cardiology, 2002, 18, 604-24.	1.7	25
39	Calcium antagonism—A New concept for treating essential hypertension. American Journal of Cardiology, 1986, 57, D50-D53.	1.6	23
40	Effects of the Beta-Adrenoceptor-Blocking Agent Sotalol on Ventricular Arrhythmias in Patients with Chronic Ischemic Heart Disease. Cardiology, 1983, 70, 114-121.	1.4	22
41	Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme. Journal of Hypertension, 1988, 6, S145-147.	0.5	17
42	Masked hypertension: A common but insidious presentation of hypertension. Canadian Journal of Cardiology, 2006, 22, 617-620.	1.7	16
43	Serum Lipid Profile Determines Platelet Reactivity to Native and Modified LDL-Cholesterol in Humans. Thrombosis and Haemostasis, 1994, 71, 627-632.	3.4	14
44	Ticrynafen: Kinetics, protein binding, and effects on serum and urinary uric acid. Clinical Pharmacology and Therapeutics, 1978, 23, 697-702.	4.7	13
45	Role of α-Adrenoceptor-Mediated Vasoconstriction for Antihypertensive β-Blockade. Journal of Cardiovascular Pharmacology, 1982, 4, S162-S167.	1.9	12
46	Temperature-dependence of LDL binding and activation of human platelets. Thrombosis Research, 1991, 64, 503-508.	1.7	12
47	Changing Role of Beta- and Alpha-Adrenoreceptor-Mediated Cardiovascular Responses in the Transition from High-Cardiac Output into a High-Peripheral Resistance Phase in Essential Hypertension. , 1981, , 316-326.		12
48	Applying the 2005 Canadian Hypertension Education Program recommendations: 1. Diagnosis of hypertension. Cmaj, 2005, 173, 480-483.	2.0	9
49	High normal blood pressure and prehypertension: The debate continues. Canadian Journal of Cardiology, 2007, 23, 581-583.	1.7	9
50	Smoking, Antihypertensive Treatment Benefit, and Comprehensive Antihypertensive Treatment Approach. Journal of Cardiovascular Pharmacology, 1990, 16, S77-S80.	1.9	9
51	The adrenaline -α2-adrenoceptor-mediated vasoconstrictor axis. Clinical Science, 1985, 68, 141s-146s.	0.0	8
52	Hemodynamic and Antihypertensive Treatment Responses with Calcium Antagonists. Journal of Cardiovascular Pharmacology, 1985, 7, S126-S130.	1.9	7
53	Treatment of dyslipidemia: The problem of reaching the goal. Atherosclerosis, 2014, 236, 142-143.	0.8	7
54	Treatment Resistant Hypertension. American Journal of Therapeutics, 2008, 15, 351-355.	0.9	6

#	Article	IF	CITATIONS
55	Do Recommendations for the Management of Hypertension Improve Cardiovascular Outcome? The Canadian Experience. International Journal of Hypertension, 2011, 2011, 1-3.	1.3	5
56	The question of the role of ethnicity on cardiovascular risk: does it matter where we come from?. Journal of Hypertension, 2005, 23, 1331-1333.	0.5	4
57	Targeting Hypertension in Patients with Cardiorenal Metabolic Syndrome. Current Hypertension Reports, 2012, 14, 397-402.	3.5	4
58	MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): A Review & Study Protocol. Current Hypertension Reports, 2015, 17, 533.	3.5	4
59	Sympathetic Nervous System in Essential Hypertension and Antihypertensive Response to α2-Adrenoceptor Stimulation. Journal of Cardiovascular Pharmacology, 1984, 6, S753-5756.	1.9	2
60	Verapamil-induced vasodilator response is enhanced in essential hypertension. General Pharmacology, 1983, 14, 185-188.	0.7	1
61	Antihypertensive treatment in patients with cerebrovascular disease: the lower the better?. Journal of Hypertension, 2010, 28, 1380-1381.	0.5	1
62	Adrenaline and Enhanced Vasoconstriction in Patients with Essential Hypertension. Basic and Clinical Pharmacology and Toxicology, 1988, 63, 41-44.	0.0	0
63	Ischemic ECG changes are found more often in asymptomatic men with a coronary prone behaviour pattern. Journal of Psychosomatic Research, 1993, 37, 355-360.	2.6	0
64	Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets. Progress in Experimental Cardiology, 2003, , 107-118.	0.0	0